医学
特应性皮炎
湿疹面积及严重程度指数
皮肤科生活质量指数
生活质量(医疗保健)
安慰剂
医院焦虑抑郁量表
萧条(经济学)
疾病严重程度
评定量表
内科学
皮肤病科
焦虑
物理疗法
疾病
精神科
替代医学
病理
经济
护理部
宏观经济学
发展心理学
心理学
作者
Eric L. Simpson,Andreas Wollenberg,Robert Bissonnette,Jonathan I. Silverberg,Jocelyne Papacharalambous,Linda Zhu,Weidong Zhang,Jean S. Beebe,Michael S. Vincent,Elena Peeva,Andrew G. Bushmakin,Joseph C. Cappelleri,Linda Chen,Vanja Sikirica,Jason Xenakis
出处
期刊:Dermatitis
[Ovid Technologies (Wolters Kluwer)]
日期:2021-04-02
卷期号:32 (1S): S53-S61
被引量:16
标识
DOI:10.1097/der.0000000000000725
摘要
Background Moderate-to-severe atopic dermatitis (AD) is inadequately controlled with current treatments for many patients. Abrocitinib is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of AD. Objective The aim of the study was to evaluate patient-reported outcomes in a phase 2b study of abrocitinib in adults with moderate-to-severe AD inadequately controlled by topical therapy (NCT02780167). Methods Patients (N = 267) were randomly assigned 1:1:1:1:1 to 12-week, once-daily abrocitinib (200, 100, 30, 10 mg) or placebo. Patient-reported outcomes included pruritus numeric rating scale (average), Patient Global Assessment, Patient-Oriented Eczema Measure, Pruritus and Symptoms Assessment for AD, Dermatology Life Quality Index, and Hospital Anxiety and Depression Scale (HADS). Results Abrocitinib 200 or 100 mg resulted in significantly greater improvements from baseline versus placebo in peak pruritus numeric rating scale (by days 2 and 3, respectively), Patient-Oriented Eczema Measure, Pruritus and Symptoms Assessment for AD, Dermatology Life Quality Index, and HADS (200 mg only, by week 1 or 2), and proportions of the patients with Patient Global Assessment clear/almost clear with 2-point or greater improvement (by weeks 1 and 4, respectively) that continued through week 12 (except HADS). Conclusions Abrocitinib treatment resulted in rapid (2 days to 2 weeks) and persistent improvements in AD symptoms and impacts in moderate-to-severe disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI